T. Kashiyama

发表

Low‐grade endometrial stromal sarcoma developing in a postmenopausal woman under toremifene treatment for breast cancer

S. Kōzuma, D. Maeda, S. Nakagawa, 2013, The journal of obstetrics and gynaecology research.

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.

H. Aburatani, S. Kōzuma, Y. Taketani, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Kaempferol, a natural dietary flavonoid, suppresses 17β-estradiol-induced survivin expression and causes apoptotic cell death in endometrial cancer.

H. Kuramoto, Tomohiko Fukuda, K. Oda, 2018, Oncology letters.

Role of multifunctional transcription factor TFII-I and putative tumour suppressor DBC1 in cell cycle and DNA double strand damage repair

K. Oda, H. Masai, T. Yano, 2013, British Journal of Cancer.

Blood Vessel Invasion Is a Strong Predictor of Postoperative Recurrence in Endometrial Cancer

M. Fukayama, K. Oda, Y. Osuga, 2018, International Journal of Gynecologic Cancer.

Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas

H. Aburatani, S. Kōzuma, Y. Taketani, 2012, PloS one.

Lymphopenia after induction chemotherapy correlates with incomplete surgical resection in patients with advanced ovarian cancer

T. Yasugi, N. Kino, S. Okada, 2018, International Journal of Clinical Oncology.

Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.

H. Aburatani, K. Oda, Y. Osuga, 2019, Gynecologic oncology.

The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition.

H. Kuramoto, Tomohiko Fukuda, K. Oda, 2015, Gynecologic oncology.

The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells

K. Oda, Y. Osuga, Shinya Oki, 2020, Oncology letters.

Significance of survivin as a prognostic factor and a therapeutic target in endometrial cancer.

H. Kuramoto, Tomohiko Fukuda, K. Oda, 2016, Gynecologic oncology.

Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.

H. Kuramoto, Tomohiko Fukuda, K. Oda, 2015, Gynecologic oncology.

Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells

H. Kuramoto, A. Enomoto, K. Miyagawa, 2014, BMC Cancer.

Cyclin D1 harboring the T286I mutation promotes oncogenic activation in endometrial cancer.

S. Kōzuma, M. Fukayama, D. Maeda, 2013, Oncology reports.

Autophagy inhibition augments resveratrol-induced apoptosis in Ishikawa endometrial cancer cells

Tomohiko Fukuda, K. Oda, T. Yano, 2016, Oncology letters.

MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53

H. Aburatani, Tomohiko Fukuda, K. Oda, 2016, Oncotarget.

Antitumor Activity and Induction of TP53-Dependent Apoptosis toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423

H. Aburatani, Tomohiko Fukuda, F. McCormick, 2014, PloS one.

Perspectives on targeting the phosphatidylinositol 3-kinase pathway for personalized medicine in endometrial and ovarian cancers

K. Oda, Y. Osuga, K. Kawana, 2016 .

Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer

H. Kuramoto, M. Fukayama, D. Maeda, 2017, Oncotarget.

Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer

Y. Osuga, M. Komatsu, S. Kaneko, 2020, Biomolecules.

Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy

Tomohiko Fukuda, D. Maeda, K. Oda, 2015, British Journal of Cancer.

Postradiotherapy persistent lymphopenia as a poor prognostic factor in patients with cervical cancer receiving radiotherapy: a single-center, retrospective study

T. Yasugi, N. Kino, K. Karasawa, 2020, International Journal of Clinical Oncology.

Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies

Tomohiko Fukuda, K. Oda, Y. Osuga, 2016, The journal of obstetrics and gynaecology research.

Coexistent Activating Mutations in the Ras / PI 3 k Pathway Potentiate Malignant Transformation of Epithelial Cells in Endometrial and Other Tissues

Tomohiko Fukuda, K. Oda, Y. Osuga, 2016 .

Extreme skeletal muscle loss during induction chemotherapy is an independent predictor of poor survival in advanced epithelial ovarian cancer patients

T. Yasugi, N. Kino, Y. Nakajima, 2020, The journal of obstetrics and gynaecology research.

The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation

K. Oda, Y. Osuga, Shinya Oki, 2019, BMC Cancer.

Title Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging

Tomohiko Fukuda, K. Aoki, K. Oda, 2018 .

The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation

K. Oda, Y. Osuga, Shinya Oki, 2019, BMC Cancer.

A low albumin to globulin ratio with a high serum globulin level is a prognostic marker for poor survival in cervical cancer patients treated with radiation based therapy

T. Yasugi, N. Kino, Y. Nakajima, 2019, International Journal of Gynecologic Cancer.

High neutrophil‐to‐lymphocyte ratio is a predictor of short‐term survival for patients with recurrent cervical cancer after radiation‐based therapy

T. Yasugi, N. Kino, Y. Nakajima, 2021, The journal of obstetrics and gynaecology research.

Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging

Tomohiko Fukuda, K. Aoki, K. Oda, 2016, Oncotarget.